BusinessCyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic LeukemiaBy Nasdaq OMXApr 17, 2018, 1:00 PM UTC
BusinessCyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual MeetingBy Nasdaq OMXApr 16, 2018, 11:01 AM UTC
BusinessPhase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual MeetingBy Nasdaq OMXMar 15, 2018, 11:01 AM UTC
